Division of AstraZeneca PLC
Latest From AstraZeneca KK
Asajes Ventures sees itself as offering a unique new mixed business model of venture capital and local development activity for smaller Western companies looking to develop their product or pipeline assets in Japan and China, aided by new opportunities from a rapidly reforming regulatory environment.
The new month brings a flurry of personal moves in pharma’s corporate and regulatory landscape in Asia Pacific. AZ Japan has a new president, Takeda has a new GM for its incubator, and China's top health regulator appoints three high-level officials.
Multinational drug makers continue shuffling their senior management in Asia as Gilead Sciences has a new president for Japan, and so does Bristol-Myers Squibb. WuXi NextCode hires a new chief digital officer.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.